Hormonal Therapy Treatment Pattern For Breast Cancer Patients At Dr. Moewardi Hospital, Surakarta
DOI:
https://doi.org/10.47701/bfz6xt62Keywords:
breast cancer, hormonal therapy, treatment patternAbstract
Breast cancer is a cancer with a high prevalence and mortality rate in women. One of the main therapies for hormone receptor-positive patients isAdjuvant Endocrine Therapy (AET) in the form of tamoxifen, either alone or in combination. The study aims to determine patient characteristics and patterns of hormonal therapy use.breast cancer patients at Dr. Moewardi Regional Hospital, Surakarta. The study used a randomized controlled study design.cross sectional with technique purposive samplingThe study subjects were 64 breast cancer patients undergoing tamoxifen therapy for at least one month. Data were obtained from medical records and questionnaires, then tested using Chi-Square see the relationship between variables. The results of the study showed that the majority of patients were aged <50 years (60.9%) and were in advanced stages (III–IV) at 57.8%. The most common type of therapy was a combination of chemotherapy and hormones (51.6%), while single hormonal therapy was used in 48.4% of patients. The most frequently used chemotherapy regimen was a combination of Cyclophosphamide & Epirubicin, while the most common hormonal therapy was Tamoxifen + Zoladex. Bivariate analysis showed a significant relationship between age and type of therapy and stage and type of therapy (p<0.05).
References
Aprilianty, D., Rafidah, Suhrawardi, & Rusmilawaty. (2024). Studi Literatur Faktor Risiko Yang Berhubungan Dengan Kejadian Kanker Payudara Pada Wanita. Jurnal Cakrawala Ilmiah, 3(9), 2473–2486.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
Burstein, H. J., Demichele, A., Fallowfield, L., Somerfield, M. R., & Lynn Henry, N. (2024). Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer - Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update. Journal of Clinical Oncology, 42(12), 1450–1453. https://doi.org/10.1200/JCO.24.00248
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 30(8), 1194–1220. https://doi.org/10.1093/annonc/mdz173
Dyanti, G. A. R., & Suariyani, N. L. P. (2016). Faktor-Faktor Keterlambatan Penderita Kanker Payudara Dalam Melakukan Pemeriksaan Awal Ke Pelayanan Kesehatan. Jurnal Kesehatan Masyarakat, 11(2), 276. https://doi.org/10.15294/kemas.v11i2.3742
Fadhil, M., Harahap, W. A., & Rusnita, D. (2019). Hasil Pengobatan Adjuvan Tamoxifen pada Pasien Kanker Payudara di RSUP Dr. M. Djamil Padang. Cdk-281, 46(12), 748–752.
Fallowfield, L. J., Hall, A., Maguire, G. P., & Baum, M. (1990). Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial. British Medical Journal, 301(6752), 575–580. https://doi.org/10.1136/bmj.301.6752.575
Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Bailey, J., Burstein, H. J., Chen, N., Chew, H., Dang, C., Elias, A. D., Giordano, S. H., Goetz, M. P., Jankowitz, R. C., Javid, S. H., Krishnamurthy, J., … Kumar, R. (2024). Breast Cancer, Version 3.2024. JNCCN Journal of the National Comprehensive Cancer Network, 22(5), 331–357. https://doi.org/10.6004/jnccn.2024.0035
Kemenkes RI. (2022). Profil Kesehatan Indonesia 2021. In Pusdatin.Kemenkes.Go.Id.
Manfrini, O., Cenko, E., Bergami, M., Yoon, J., Kostadinovic, J., Zdravkovic, D., Zdravkovic, M., & Bugiardini, R. (2025). Anticancer-Drug-Related Cardiotoxicity from Adjuvant Goserelin and Tamoxifen Therapy. Journal of Clinical Medicine, 14(2). https://doi.org/10.3390/jcm14020484
N’Da, D. D., Breytenbach, J. C., Smith, P. J., & Lategan, C. (2010). Synthesis, cytotoxicity and antimalarial activity of ferrocenyl amides of 4-aminoquinolines. Arzneimittel-Forschung/Drug Research, 60(10), 627–635. https://doi.org/10.1055/s-0031-1296337
Orrantia-Borunda, E., Achondo-Nunez, P., Acuna-Aguilar, Evelia, L., Gomez-Valles, Octavia, F., & Ramirez-Valdespino, Adriana, C. (2022). Chapter 3: Subtypes of Breast Cancer. In Subtype of Breast Cancer. https://pubmed.ncbi.nlm.nih.gov/36122153/
Regan, M. M., Pagani, O., Walley, B., Torrisi, R., Perez, E. A., Francis, P., Fleming, G. F., Price, K. N., Thürlimann, B., Maibach, R., Castiglione-gertsch, M., Coates, A. S., Goldhirsch, A., & Gelber, R. D. (2008). Premenopausal endocrine-responsive early breast cancer: Who receives chemotherapy? Annals of Oncology, 19(7), 1231–1241. https://doi.org/10.1093/annonc/mdn037
Shidqi, Z. N., Saraswati, L. D., Kusariana, N., Sutiningsih, D., & Udiyono, A. (2022). Faktor-Faktor Keterlambatan Diagnosis Kanker Pada Pasien Kanker Payudara : Systematic Review. Jurnal Epidemiologi Kesehatan Komunitas, 7(2), 471–481. https://doi.org/10.14710/jekk.v7i2.14911
Siska, M., Kusumastuti, T., & Cholisoh, Z. (2024). Gambaran Adverse Drud Reaction (ADRs) pada Pasien Kanker Payudara yang Mendapatkan Adjuvant Endocrine Therapy (AET) Tamoxifen dan Faktor-faktor yang Mempengaruhinya di RS Swasta Semarang Tahun 2023. Jurnal Ners Universitas Pahlawan, 8(1), 96–101. http://journal.universitaspahlawan.ac.id/index.php/ners
Sperry, L. (2020). Breast Cancer. Behavioral Health, 171–181. https://doi.org/10.4324/9780203084632-26
Sutrisno, Nurmalik, M. C. A., & Aripuspita, E. (2024). Hubungan Antara Usia Dan Lama Penggunaan Kontrasepsi Hormonal Dengan Stadium Pada Kanker Payudara Di Rsud Dr. Soegiri Lamongan. JurnalMU: Jurnal Medis Umum, 1(3), 198–208. https://doi.org/10.30651/jmu.v1i3.24776
American Cancer Society. (2019). Breast Cancer Facts & Figures 2019–2020. Atlanta: American Cancer Society.
ASCO Guidelines. (2022). Endocrine Therapy for Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline. Journal of Clinical Oncology.
NCCN. (2024). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. National Comprehensive Cancer Network.
The Global Cancer Observatory. (2021). Cancer Today. International Agency for Research on Cancer (IARC).
World Health Organization. (2022). Breast cancer: Prevention and control. WHO.
